Evidence map›Paper›PMID 40474081›Full record

ArticleBMC medical research methodology2025

Value-adaptive clinical trial designs for efficient delivery of publicly funded trials - a discussion of methods, case studies, opportunities and challenges.

Laura Flight, Alan Brennan, Stephen E Chick, Martin Forster, Steven Julious, Puvan Tharmanathan

Abstract read
In one paragraph

Article in BMC medical research methodology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Review
  3. Comment: Advancing Clinical Trials with Novel Designs and Implementations.Statistical science : a review journal of the Institute of Mathematical Statistics · 2023
    Article
  4. Expected Value of Sample Information to Guide the Design of Group Sequential Clinical Trials.Medical decision making : an international journal of the Society for Medical Decision Making · 2022
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Laura FlightSheffield Centre for Health and Related Research (SCHARR), School of Medicine and Population Health, University of Sheffield, Regent Court, 30 Regent Street, Sheffield, S1 4DA, UK.ORCID 0000-0002-9569-8290
Alan BrennanSheffield Centre for Health and Related Research (SCHARR), School of Medicine and Population Health, University of Sheffield, Regent Court, 30 Regent Street, Sheffield, S1 4DA, UK. a.brennan@sheffield.ac.uk.ORCID 0000-0002-1025-312X
Stephen E ChickINSEAD, Technology and Operations Management Area, Fontainebleau, France.ORCID 0000-0002-8026-1571
Martin ForsterDepartment of Statistical Sciences 'Paolo Fortunati', University of Bologna, Bologna, Italy.ORCID 0000-0001-8598-9062
Steven JuliousSheffield Centre for Health and Related Research (SCHARR), School of Medicine and Population Health, University of Sheffield, Regent Court, 30 Regent Street, Sheffield, S1 4DA, UK.ORCID 0000-0002-9917-7636
Puvan TharmanathanYork Trials Unit, Department of Health Sciences, University of York, York, UK.ORCID 0000-0001-9196-0207

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundValue-adaptive designs for clinical trials are a novel set of emerging methods for delivering greater value for clinical research. There is increasing interest in using them within publicly funded health systems. A value-adaptive design permits 'in progress' changes to be made to the trial according to criteria which reflect its overall value to the healthcare system, including the cost-effectiveness of the technologies under investigation, the cost of running the trial and the total health benefit delivered to patients. These trial designs offer the potential to explicitly balance the costs and benefits of adaptive clinical trials with the health economic benefits expected for populations that are affected by any subsequent health technology adoption decisions. They may also improve the expected value of learning from the budget that is spent within a trial. MAIN BODY: This paper introduces value-adaptive designs for publicly funded clinical trials. It discusses the idea of delivering 'value for money' in health technology assessment, what is meant by being 'value-adaptive' and the key features that characterise these designs. The methodology behind one kind of value-adaptive design - the value-based sequential model of a two-armed clinical trial proposed by Chick et al. (2017) - is described and illustrated using three retrospective case studies from the United Kingdom. The paper concludes by reviewing a range of perspectives provided by stakeholders, together with our own thoughts, on the practical opportunities and changes required for implementing a value-adaptive approach.

conclusionsValue-adaptive clinical trial designs offer the potential to align health research funding allocations with population health economic goals. Many of the systems required to deploy value-adaptive designs within a publicly funded health system already exist and, with increased application, experience, and refinement they have the potential to deliver improved value for money.

Indexed as

Adaptive Clinical Trials as TopicResearch DesignTechnology Assessment, BiomedicalCost-Benefit AnalysisDelivery of Health CareHumansAdaptive designsCost-effective researchHealth economicsValue-adaptive clinical trial design

Identifiers

PMID40474081
PMCPMC12139198

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.